How has been the historical performance of Rossari Biotech?

Answer:The historical performance of Rossari Biotech shows a consistent growth trajectory in net sales and profitability over the years.

Breakdown:
Rossari Biotech's net sales have increased significantly from INR 600.09 crore in March 2020 to INR 2,080.29 crore in March 2025, reflecting a strong upward trend. Total operating income has followed a similar pattern, rising from INR 600.09 crore in March 2020 to INR 2,080.29 crore in March 2025. The company's operating profit (PBDIT) has also shown growth, reaching INR 269.08 crore in March 2025, up from INR 108.46 crore in March 2020. Profit before tax has increased from INR 88.06 crore in March 2020 to INR 184.21 crore in March 2025, while profit after tax has grown from INR 65.47 crore to INR 135.40 crore over the same period. The earnings per share (EPS) have risen from INR 12.86 in March 2020 to INR 24.64 in March 2025, indicating improved shareholder value. On the balance sheet, total assets have expanded from INR 471.46 crore in March 2020 to INR 1,885.67 crore in March 2025, with total liabilities also increasing from INR 471.46 crore to INR 1,885.67 crore. Cash flow from operating activities has improved significantly, reaching INR 137 crore in March 2025 compared to INR 56 crore in March 2020, while the closing cash and cash equivalents have increased from INR 29 crore to INR 44 crore during the same period. Overall, Rossari Biotech has demonstrated robust growth in sales, profits, and cash flow, alongside a solid balance sheet position.